Ottawa-Shanghai Joint School of Medicine


WU Xueling

Email: wuxueling76@126.com

Tel: 18321035326

RESEARCH INTEREST: chronic airway inflammation,lung cancer, PE

Biography

  • I was 46 years old, MD and PhD, the chief physician of the respiratory department of Renji Hospital.

  • I graduated from the Third Military Medical University in 2005 with a Doctor's degree. I worked at Xinqiao Hospital,Third Military Medical University from 2005 to 2015 and renji hospital from 2015 to now. I worked at Zhongshan hospital, Fudan University as a postdoctor from 2009 to 2011.From 2016 to 2017, he was a visiting scholar at the University of California, San Francisco.

  • Reviewer of the National Natural Science Foundation of China, member of the Pulmonary Embolism and Pulmonary Vascular Disease Group of the 9th Committee of the Respiratory Society of the Chinese Medical Association from 2014 to 2017; In 2020, he served as the first member of the mediastinum and pleura group of the Respiratory Society of the Chinese Medical Association;

  • Since 2016, he has successively served as the 10th and 11th Youth Members of Respiratory Branch of Shanghai Medical Association; Since 2016, he has successively served as a member of the Lung Cancer Group of the Respiratory Branch of Shanghai Medical Association. Member of Immunotherapy Committee of China Lung Cancer Prevention and Treatment Alliance; Member of China Internet of Things Alliance and member of China Metacosmic Medicine.

  • He served as a peer reviewer for several journals, including Chinese Journal of Pulmonary Diseases, Chinese Journal of Experimental and Clinical Infectious Diseases, Journal of Geriatrics and Health Care, Inflammation Research, Shock, etc.

  • At present, it has presided over 3 National Natural Science Foundation projects, 4 provincial and ministerial level projects, and 2 academic level projects.

Publications

  1. XL Wu, GS Qian, Y Zhao, D Xu. LBP inihibitory peptide reduced endotoxin-induced macrophage activation and mortality. Inflamm Res. 2005(54):451-457.

  2. Zhang C, Wu X, Zhao Y, Deng Z, Qian G.SIGIRR inhibits Toll-Like Receptor 4, 5, 9-mediated immune responses in Human Airway Epithelial Cells. Mol Biol Rep. 2011,38(1):601-609.

  3. Chen X, Zhao Y, Wu X, Qian G. Enhanced Expression of Single Immunolobuling IL-1 Receptor-related Moleclue Ameliorates Lipopolysaccharide-induced Acute Lung Injury In Mice. Shock, 2011, 35(2):198-204.

  4. Chen X, Wu X, Zhao Y, Wang G, Feng J, Li Q, Qian G.A novel binding protein of single immunoglobulin IL-1 receptor-related molecule: Paralemmin-3.Biochem Biophys Res Commun, 2011,404(4):1029-1033.

  5. Zhao Y, Xiong W, Wu X. A Case of Pulmonary Alveolar Proteinosis secondary with but prior to Myelodysplastic Syndrome. Respirol Case Rep. 2013,1(2):58-61

  6. Zhao YF, Jiang YP, Zhou LF, Wu XL.The value of assessment tests in patients with acute exacerbation of chronic obstructive pulmonary disease.Am J Med Sci. 2014 ,347(5):393-399.

  7. Guo L, Li SY, Ji FY, Zhao YF, Zhong Y, Lv XJ, Wu XL, Qian GS. Role of Angptl4 in vascular permeability and inflammation. Inflamm Res. 2014;63(1):13-22.

  8. Zhao YF, Xiong W, Wu XL. Mesenchymal stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice.Mol Med Rep. 2014 ;9(5):1583-1589.

  9. Zhao YF, Luo YM, Xiong W, Wu XL.Genetic variation in ORMDL3 gene may contribute to the risk of asthma: A meta-analysis.Hum Immunol,2014,75(9):960-967.

  10. Liao JR, Zhang D, Wu XL. Pulmonary tuberculosis combined with hepatic tuberculosis: a case report and literature review. Clin Respir J. 2015 Oct;9(4):501-5

  11. Guo L, Li S, Zhao Y, Qian P, Ji F, Qian L, Wu X*, Qian G*.Silencing angiopoietin-like protein 4 (ANGPTL4) protects against  lipopolysaccharide-induced acute lung injury via regulating SIRT1/NF-kB pathway.J Cell Physiol. 2015 Oct;230(10):2390-402. doi: 10.1002/jcp.24969

  12. Zhao YF, Luo YM, Xiong W, Ding W, Li YR, Zhao W, Zeng HZ, Gao HC, Wu XL.Mesenchymal stem cell-based FGF2 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Eur Rev Med Pharmacol Sci.2015;19(5):857-65

  13. Li S, Guo L, Qian P, Zhao Y, Liu A, Ji F, Chen L, Wu X, Qian G.Lipopolysaccharide Induces Autophagic Cells Death through Unfolded Response in Human Alveolar Epithelial A549 Cells. Cell PhysiolBiochem. 2015;36(6):2403-17.

  14. Li S, Guo L, Zhao Y, Qian P, Lv X, Qian L, Wang Q, Qian G, Yao W, Wu X. Silencing of Paralemmin-3 Protects Mice from lipopolysaccharide-induced acute lung injury.Peptides. 2016 Feb;76:65-72

  15. Zhang S, Zhao YF, Zhang MZ, Wu XL. The Value of tumor markers in bronchoalveolar lavage fluid in the diagnosis of peripheral pulmonary carcinoma. Clin Respir J. 2017 Jul;11(4):481-488

  16. Yu Xu, Yunfeng Zhao, Yuliang Liu, Lanlan Qian, Wei Yao, Xuefeng Tang, Xueling Wu A rare case of synchronous mycobacterium, tuberculosis, aspergillosis and lung adenocarcinoma in a patient. Int J Clin Exp Pathol 2016;9(12):13010-13014.

  17. Qian L, Zhao Y, Guo L, Li S, Wu X. Activating transcription factor 3 (ATF3) Protects Against Lipopolysaccharide-Induced Acute Lung Injury Via inhibiting the expression of TL1A. J Cell Physiol. 2017 Dec;232(12):3727-3734.

  18. Zhao Y, Wu X, Qian L, Guo L, Liao J, Wu X. Activating transcription factor 3 protects mice against pseudomonas aeruginosa-induced acute lung injury by interacting with lipopolysaccharide binding protein. Mol Immunol. 2017 Jun 26;90:27-32

  19. Yunfeng Zhao ,Xiaoyuan Sun ,Xueling Wu.A Case of Disseminated Talaromyces marneffei in the Host with Normal Immunity .journal of clinical radiology and case reports.2017,1(2):1-4.

  20. Wu X, Sun X, Liu B, Zhao Y. Enhanced Expression of Robo4 Ameliorates LPS Induced Acute Lung Injury in Mice through Binding to Rhoa. Immunome Res, 2018,14: 160. doi: 10.4172/17457580.1000160.

  21. Gotts JE, Bernard O, Chun L, Croze RH, Ross JT, Nesseler N, Wu X, Abbott J, Fang X, Calfee CS, Matthay MA.Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice.

  22. Am J Physiol Lung Cell Mol Physiol. 2019 Nov 1;317(5):L717-L736.

  23. Wu X, Guo L, Li S, Zheng Y, Fan B, Zhou C.Low-grade myofibroblastic sarcoma with abdominal pain, a stuffy nose, hearing loss, and multiple cavity effusion: a case report and literature review. J Int Med Res. 2020 Jan;48(1):300060519895661.

  24. Guo L, Wu X, Zhao S, Zhang X, Qian G, Li S.Autophagy inhibition protects from alveolar barrier dysfunction in LPS-induced ALI mice by targeting alveolar epithelial cells. Respir Physiol Neurobiol. 2020 Sep 17:103532. doi: 10.1016/j.resp.2020.103532

  25. Cui YQ, Tan XM, Liu B, Zheng Y, Zhang LY, Chen ZA, Wu XL. Analysis on risk factors of lung cancer complicated with pulmonary embolism. Clin Respir J. 2021 Jan;15(1):65-73. doi: 10.1111/crj.13270.

  26. Wu X, Yang G, Chen S, Tang M, Jian S, Chen F, Wu X.Bartter syndrome with long-term follow-up: a case report.J Int Med Res. 2020 Aug;48(8):300060520947876. doi: 10.1177/0300060520947876.

  27. Zheng Y, Lou Y, Zhu F, Wang X, Wu W, Wu X.Utility of fractional exhaled nitric oxide in interstitial lung disease.J Breath Res. 2021 Jun 16;15(3). doi: 10.1088/1752-7163/ac01c1.

  28. Fan B,Tan X, Lou Y, Zheng Y,Zhang L, Wu X. Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study . J Int Med Res. 2021 Oct;49(10):3000605211046173.

  29. Qiong Xu#, Qiongfang Cha, Hui Qin, Bin Liu, Xueling Wu*,Jiantao Shi*. Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Q2 Adenocarcinoma. Frontiers in Bioinformatics. doi: 10.3389/fbinf.2022.813960.

  30. Yunfeng Zhao, Liang Guo, Shaoying Li, Xueling Wu.Del-1reduces endotoxin-induced polymorphonuclear leukocytes adhension and mortality.European Respiratory Journal Sep 2013, 42 (Suppl 57) 389

  31. Li S, Qian P,Guo L, Qian G, Wu X. Lipopolysaccharide Induces Autophagic Cells Death Through Unfolded Protein Response in Human Alveolar Epithelial A549 Cells. Am J Respir Crit Care Med 191; 2015: A4364 (ATS poster)

  32. Z AO, X WU. Activating transcription factor 3 (ATF3) Protects Against pseudomonas aeruginosa-Induced Acute Lung Injury Via binding to LBP Respirology,2016,21(Suppl. 3): 150

  33. Q. LANLAN, W XUELING. Activating transcription factor 3 (ATF3) Protects Against Lipopolysaccharide-Induced Acute Lung Injury Via inhibiting the expression of TL1A. Respirology,2016,21(Suppl. 3): 210

  34. Differentially expressed circular RNAs in human pleural metastatic lung cancer and clinical significance. 2019 the Japanese Society of Medical Oncology Annual Meeting.